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 ■ INTRODUCTION
Bone cancers derive from primitive mesenchymal cells 
comprising a variety of tumors including osteosarcoma (OS), Ewing 
sarcoma (ES), chondrosarcoma (CS) and other rarer subtypes. Bone 
cancers account for 3 to 8% of malignancies affecting the 0 to 
19 year age group and for 3% of all cancer cases among adolescents 
and young adults (AYA) aged 15 to 29 years (1,2).
OS and ES are the most frequent morphological subtypes of 
bone cancers presenting a worldwide distribution of about 20 to 
40% and 6 to 8% of all bone tumors, respectively  (3,4). Except 
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in the first decade of life, OS occurs more frequently in males. 
Approximately 80% of patients with ES are younger than 20 years, 
with the peak incidence occurring during the second decade of life. 
CS is the most common subtype in older patients (3,5).
Despite improvements in treatment, children and adolescents 
with bone cancers still present a high mortality, being the third most 
frequent cause of death related to cancer in England (6). In Brazil, 
mortality in 15-19 years age group due to bone cancers was reported 
at five cases per million, decreasing to three cases per million in 
20-29 years age group (7).
In this study, our aim was to describe incidence and mortality 
trends of bone cancers, considering the subtypes, among children 
(0-14 years) and AYA (15-29 years) in Brazil. 
 ■ METHODS
Information about incidence was obtained from 23 population-
based cancer registries (PBCR) covering the five geographic regions 
of Brazil: North (four PBCR), Northeast (seven PBCR), Midwest 
(three PBCR), Southeast (six PBCR) and South (three PBCR) that 
correspond to 23% of the total Brazilian population (North, 32%; 
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Northeast, 22%; Midwest, 39%; Southeast, 22% and South 13%). 
Data quality indicators can be seen in Supplemental Table S1.
Morphological subtypes of bone cancers as well as sites of 
involvement were classified according to the third edition of 
International Classification of Childhood Cancer (ICCC-3) among 
children, and according to the WHO Classification for AYA (8,9).
To evaluate the frequency of bone cancers in different 
topographies, all cases were classified according to the codes of 
the International Classification of Diseases for Oncology – third 
edition (ICD-O-3): C400 – long bones of the upper limb, scapula 
and associated joints; C401 – short bones of the upper limbs 
and associated joints; C402 – long bones of the lower limbs and 
associated joints; C403 – short bones of the lower limbs and 
associated joints; C408 – overlapping lesions of bones, joints 
and articular cartilage of the limbs; C409 – bone of the limbs, not 
otherwise specified (NOS); C410 – bones of the skull and face and 
associated joints; C411 – mandible; C412 – vertebral column; C413 
– rib, sternum, clavicle and associated joints; C414 – pelvic bones, 
sacrum, coccyx and associated joints; C418 – overlapping lesions 
of bones, joints and articular cartilage; and C419 – bone, NOS.
Data for the mortality analysis were extracted from the On-line 
Atlas of Cancer Mortality databases (https://mortalidade.inca.
gov.br) from 1979 to 2013, as provided by the Brazilian Health 
Mortality Information System (SIM). The cause of death was 
based on the International Classification of Diseases and Related 
Health Problems versions 9 (ICD-9; 1979–95) and 10 (ICD-10; 
1996–2008). The codes for bone cancers were C-40 (bone and joints 
of the limbs) and C-41 (bones and joints of other sites). Mortality 
considered the five geographic regions of Brazil.
Incidence trends were evaluated in six PBCR for children and in 
12 PBCR for AYA which had eight years of database consolidation. 
PBCR with rate values of zero were excluded. Mortality trends 
were analyzed according to the five geographic regions of Brazil. 
Statistical analyses
Age-specific incidence rates (ASIR) per million population 
were analyzed for each morphological subtype of bone tumor 
according to gender and age at diagnosis (stratified into: 0 to 4 
years, 5 to 9 years, 10 to 14 years, 15 to 19 years, 20 to 24 years, 
and 25 to 29 years). Age-adjusted incidence rates (AAIR) and 
age-adjusted mortality rates (AAMRs) were performed in those 
aged 0 to 14 years and 15 to 29 years and estimated based on the 
world population proposed for groups aged less than 30 years (10). 
Median incidence rates were used to measure central tendency and 
to obtain an overall assessment of incidence rates. Age-specific 
mortality rates (ASMRs) were calculated according to deaths by 
bone cancers. 
To identify significant changes in incidence and mortality 
trends, Joinpoint regression analysis was performed, and the annual 
average changes (Average Annual Percent Change [AAPC]) were 
estimated. The best cut-point period for measuring the trends is 
described elsewhere. Significance was determined with the Monte 
Carlo permutation method. 
 ■ RESULTS
Distribution by site and subgroups (ICCC-3/ WHO) of 
bone tumors 
According to morphological subtypes, long bones of the lower 
limbs was the most common affected site, corresponding to 66% 
OS and 24% ES, followed by long bones of the upper limbs (10% 
OS and 11.2% SE) and pelvic bones (3% OS and 17% ES).  
Incidence rates 
The AAIR in children was 5.74 cases per million, with highest 
rates observed in Porto Alegre, Distrito Federal and Curitiba. 
The 10-14 year age group had the highest ASIR. Among the AYA 
group, the median AAIR was 11.25 cases per million. The 15-19 
year age group had the highest rates, decreasing among those aged 
20-29 years. The highest incidence rates among the AYA group 
were seen in Florianopolis, Joao Pessoa, and Goiania (Table 1). 
According to gender, median incidence rates of all bone cancers 
were similar for children (AAIR: 5.02 per million in males; 5.85 
per million in females). For AYA, a higher incidence rate was seen 
for males (AAIR: 12.24 per million in males; 7.54 per million in 
females). Regarding the distribution of bone tumor morphological 
subtypes, OS was more frequent (47.3%), followed by ES (24.5%), 
other specific/non-specific tumors (21.8%) and CS (6.4%). Among 
other specific/non-specific tumors, more than 90% corresponded 
to non-specific bone cancers for both age groups. The incidence 
analysis by morphological subtypes of bone cancers can be seen in 
Table 2. Median incidence rates of OS among children was higher 
in females (AAIR: 2.14 per million in males; 3.12 per million in 
females) while males had the highest incidence rates among AYA 
(AAIR: 4.69 per million in males; 2.36 per million in females). 
ES showed a slight difference between genders in both children 
(AAIR: 1.11 per million in males; 1.62 per million in females) 
and AYA (AAIR: 1.81 per million in males; 1.76 per million in 
females). Incidence rates of CS had no differences between genders. 
The incidence peak of OS in females was earlier (10 to 14 years) 
compared to males (15 to 19 years) (Figure 1). 
Mortality rates
ASMR was higher among the group aged 15-19 years. The 
Midwest region had the highest ASMR in most age groups. AAMR 
was higher in AYA compared to children group (Table 3).
Incidence and mortality trends 
Among children, five PBCR showed an increased trend in 
incidence, although it was not significant. Only one PBCR (São 
Paulo) showed a significant decreased trend in incidence (AAPC: 
-4.0%). Among the AYA group, three PBCR had a significant 
decrease in trends (Recife, -6.3%; Salvador, -10.9%; and São Paulo, 
-7.0%) while most PBCR only showed a decreased non-significant 
trend in incidence. Mortality due to bone cancers among children 
had an increased trend in the North and Northeast regions (AAPC: 
4.0% and 4.5%, respectively). A significant decreased trend in 
mortality (AAPC: -0.9%) was seen in the South region. The North 
and Northeast regions also demonstrated a significant increased 
trend in mortality (AAPC: 1.2% and 3.0%, respectively) and the 
Southeast showed a stable pattern (AAPC: −0.3%) among the AYA 
group (Figure 2).
 ■ DISCUSSION
This study summarized the incidence and mortality rates of 
bone cancers in Brazil. We observed that while there was less 
variation in bone cancer subtypes, with OS and ES being prevalent 
in all regions and over time, there was incidence and mortality 
patterns variation within the geographic regions and across age 
groups, although not always significant. 
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Data presented here were collected from PBCR, allowing 
for the study of cancer trends and capturing cases from the five 
geographic regions across the country. However, on top of not 
covering all cases within Brazil, the 23 PBCR may be limited 
due to incomplete registration, preferential report of malignant 
diseases, diagnosis (histology) confirmation, region extent and 
different periods of coverage. Nevertheless, the most up-to-data 
were carefully examined and we believe that data presented here 
are a true representation, although not exact, of the bone cancer 
incidence and mortality in Brazil.
The incidence rates of bone cancers affecting children and AYA 
are similar and remain stable across countries. A recent publication 
from the International Agency for Research on Cancer, that 
included five PBCR from Brazil, reported age-adjusted incidence 
rates of bone cancer in South America (5.80 per million in ages 
0-14 years and 16.50 per million in ages 15-19 years), similar to our 
Table 1 – Incidence rates per million (ASIR; AAIR) of bone tumors in children, adolescents, and young adults according 
to age group and region.
Region PBCR
0-4 
years
5-9 years
10-14 
years
0-14 years
15-19 
years
20-24 
years
25-29 
years
15-29 years
n ASIR n ASIR n ASIR n AAIR CI (95%) n ASIR n ASIR n ASIR n AAIR CI (95%)
North Belem (2005-2009) * 1.71 * 6.12 13 19.44 18 8.24 (4.41; 12.07) 13 17.70 6 8.48 5 8.26 24 11.79 (7.06; 16.52)
Manaus  
(2002-2006)
* 1.06 * 2.29 6 7.30 9 3.24 (1.12; 5.37) 19 23.16 7 8.77 7 10.50 33 14.63 (9.62; 19.63)
Palmas  
(2008-2012)
* 0.00 * 0.00 * 19.56 * 5.64 (-2.69; 8.28) * 9.69 * 0.00 * 27.86 * 12.07 (0.18; 23.96)
 
Roraima  
(2006-2010)
* 0.00 * 0.00 * 4.26 * 1.23 (-1.19; 3.65) * 5.07 * 11.55 * 6.63 * 7.32 (0.13; 14.51)
Northeast
Aracaju  
(2007-2011)
* 4.73 * 0.00 * 8.79 * 4.38 (-0.65; 9.41) * 11.65 * 3.73 5 20.44 9 11.78 (4.07; 19.48)
Fortaleza  
(2002-2006)
* 1.81 5 4.49 21 17.75 28 7.37 (4.61; 10.12) 15 12.72 10 9.30 8 8.62 33 10.35 (6.81; 13.89)
Joao Pessoa 
(2006-2010)
* 3.82 * 3.56 * 9.90 5 5.37 (0.58; 10.17) 8 24.74 * 9.53 5 17.99 16 17.54 (8.93; 26.14)
Natal (2001-2005) * 0.00 7 20.50 * 7.93 10 9.00 (3.39; 14.61) * 10.15 * 5.60 * 0.00 6 5.42 (1.08; 9.77)
Recife (2006-2010) * 5.50 6 10.07 6 9.38 15 8.06 (3.92; 12.19) 8 11.30 6 8.60 6 9.32 20 9.84 (5.52; 14.15)
Salvador  
(2001-2005)
* 0.91 * 3.69 14 11.92 19 4.92 (2.68; 7.17) 19 13.48 9 6.53 8 7.03 36 9.06 (6.09; 12.03)
 
Teresina  
(2002-2006)
* 0.00 * 0.00 * 6.94 * 1.96 (-0.26; 4.19) 10 5.79 8 5.80 * 1.92 20 4.56 (2.54; 6.58)
Midwest
Cuiaba  
(2003-2007)
* 0.00 * 0.00 8 29.66 8 8.56 (2.62; 14.49) 5 18.22 * 0.00 * 9.14 7 9.36 (2.42; 16.30)
Distrito Federal 
(1998-2002)
* 7.37 5 6.43 15 18.84 26 10.50 (6.44; 14.56) 15 16.86 11 12.20 6 7.61 33 13.1 (8.62; 17.59)
 
Goiania  
(2005-2009)
* 0.00 * 4.03 9 17.40 11 6.31 (2.57; 10.05) 13 22.03 6 9.82 7 13.55 26 15.59 (9.56; 21.63)
Southeast
Belo Horizonte 
(2004-2008)
* 4.34 7 7.64 16 16.32 27 8.90 (5.51; 12.29) 19 17.12 20 17.25 * 3.03 42 14.69 (10.24; 19.14)
Campinas  
(2001-2005)
* 0.00 * 7.63 * 4.68 5 3.80 (0.46; 7.15) 6 13.27 * 6.35 * 4.65 11 8.37 (3.40; 13.34)
Grande Vitoria 
(2008-2012)
* 7.67 * 0.00 7 10.01 12 5.74 (2.44; 9.03) 9 11.83 5 6.96 * 4.96 17 8.2 (4.29; 12.11)
Jahu (2009-2013) * 0.00 * 0.00 * 0.00 * 0.00 - * 16.93 * 15.32 * 0.00 * 11.25 (-4.50; 27.00)
Poços de Caldas 
(2007-2011)
* 0.00 * 0.00 * 0.00 * 0.00 - * 15.93 * 0.00 * 0.00 * 5.96 (-5.72; 17.65)
 
Sao Paulo  
(2006-2010)
* 0.98 32 7.46 66 15.33 102 7.24 (5.83; 8.65) 75 4.20 49 2.76 45 2.71 169 3.26 (2.77; 3.75)
South
Curitiba  
(2006-2010)
5 8.31 5 7.42 9 12.60 19 9.37 (5.06; 13.68) 15 19.91 6 7.56 6 8.10 27 13.35 (8.31; 18.40)
Florianopolis 
(2008-2012)
* 0.00 * 0.00 * 13.64 * 3.93 (-1.52; 9.39) * 23.89 * 20.63 * 5.20 9 19.63 (6.78; 32.47)
 
Porto Alegre 
(2002-2006)
* 5.56 * 5.66 15 26.97 21 11.77 (6.69; 16.84) 12 19.18 9 14.54 * 5.65 24 13.21 (7.91; 18.51)
MEDIAN     0.98   4.03   11.92   5.74     15.93   8.48   7.03   11.25  
* Absolute value <5 cases.
AAIR: Age-adjusted incidence rates; ASIR: Age-specific incidence rates.
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Figure 1 – Age-specific incidence rates (ASIR) of Osteosarcoma in children, adolescents and young adults in Brazil, according to gender 
and age group.
Table 2 – Distribution and age-ajusted incidence rates (AAIR) of morphological subtypes of bone tumors in children, adolescents and 
young adults, according to age group and region.
Region PBCR
Osteosarcoma Chondrosarcoma Ewing Sarcoma
Other specific and  
non-specific
0-14 15-29 0-14 15-29 0-14 15-29 0-14 15-29 
(%) AAIR (%) AAIR (%) AAIR (%) AAIR (%) AAIR (%) AAIR (%) AAIR (%) AAIR
North Belem (2005-2009) 50.0 4.01 58.3 6.88 0.0 0.00 8.3 0.96 44.4 3.78 12.5 1.48 5.6 0.45 20.8 2.46
Manaus (2002-2006) 66.7 2.12 42.4 6.24 0.0 0.00 3.0 0.42 22.2 0.71 24.2 3.64 11.1 0.41 30.3 4.33
Palmas (2008-2012) 50.0 2.8 0.0 0.00 0.0 0.00 0.0 0.00 50.0 2.84 50.0 6.33 0.0 0.00 50.0 5.74
  Roraima (2006-2010) 0.0 0.00   25.0 1.78 0.0 0.00 0.0 0.00 0.0 0.00 0.0 0.00 100.0 1.23 75.0 5.54
Northeast Aracaju (2007-2011) 33.3 1.29 55.6 6.75 0.0 0.00 0.0 0.00 66.7 3.09 33.3 3.78 0.0 0.00 11.1 1.25
Fortaleza (2002-2006) 75.0 5.35 72.7 7.45 0.0 0.00 3.0 0.3 17.9 1.39 15.2 1.62 7.1 0.62 9.1 0.99
Joao Pessoa (2006-2010) 80.0 3.93 18.8 3.48 0.0 0.00 37.5 6.46 0.0 0.00 6.3 1.09 20.0 1.44 37.5 6.51
Natal (2001-2005) 60.0 5.25 33.3 1.86 0.0 0.00 16.7 0.93 20.0 1.83 33.3 1.77 20.0 1.91 16.7 0.86
Recife (2006-2010) 40.0 3.12 35.0 3.42 6.7 0.44 20.0 1.93 26.7 2.27 10.0 0.98 26.7 1.11 35.0 3.51
Salvador (2001-2005) 63.2 3.01 69.4 6.25 10.5 0.50 13.9 1.29 21.1 1.19 13.9 1.25 5.3 0.22 2.8 0.27
  Teresina (2002-2006) 33.3 0.64   55.0 2.41 0.0 0.00 0.0 0.00 33.3 0.67 15.0 0.73 33.3 0.66 30.0 1.43
Midwest Cuiaba (2003-2007) 50.0 4.26 42.9 4.06 37.5 3.19 0.0 0.00 0.0 0.00 28.6 2.7 12.5 1.11 28.6 1.6
Distrito Federal (1998-2002) 19.2 1.9 21.2 2.78 11.5 1.06 18.2 2.57 3.8 0.38 9.1 1.11 65.4 3.58 51.5 6.65
Goiania (2005-2009) 72.7 4.54 61.5 9.86 0.0 0.00 3.9 0.68 27.3 1.77 26.9 3.88 0.0 0.00 7.7 1.17
Southeast Belo Horizonte (2004-2008) 48.1 3.89   40.5 6.04 0.0 0.00 9.5 1.41 29.6 2.98 19.0 2.77 22.2 2.03 31.0 4.47
Campinas (2001-2005) 40.0 1.46 45.5 3.69 0.0 0.00 18.2 1.48 60.0 2.34 9.1 0.86 0.0 0,00 27.3 2.34
Grande Vitoria (2008-2012) 33.3 1.87 47.1 3.95 0.0 0.00 0.0 0.00 41.7 2.22 29.4 2.41 25.0 1.65 23.5 1.4
Jahu (2009-2013) 0.0 0.00 50.0 4.81 0.0 0.00 0.0 0.00 0.0 0.00 50.0 6.44 0.0 0.00 0.0 0.00
Poços de Caldas (2007-2011) 0.0 0.00 0.0 0.00 0.0 0.00 0.0 0.00 0.0 0.00 0.0 0.00 0.0 0.00 100.0 5.96
  Sao Paulo (2006-2010) 53.9 3.83   42.0 1.38 0.0 0.00 7.7 0.24 24.5 1.8 29.6 0.67 21.6 0.8 20.7 0.96
South Curitiba (2006-2010) 31.6 2.61 40.7 5.43 0.0 0.00 3.7 0.46 52.6 5.02 44.4 6.01 15.8 1.75 11.1 1.45
Florianopolis (2008-2012) 50.0 3.93 33.3 6.72 0.0 0.00 11.1 2.07 0.0 0.00 44.4 8.78 50.0 0.00 11.1 2.07
Porto Alegre (2002-2006) 38.1 4.39 58.3 7.91 0.0 0.00 8.3 1.11 47.6 5.59 16.7 2.1 14.3 1.79 16.7 2.09
MEDIAN     3.01     4.06   0.00   0.46   1.77   1.77   0.66   2.07
* Absolut value <5 cases. 
AAIR: Age-adjusted incidence rates.
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data (5,11). Previously, Brazil had median incidence rates for all 
bone cancers in children and adolescents (0-19 years) of 9.53 cases 
per million according to 14 PBCR and 9.38 cases per million in 
AYA according to 21 PBCR (12,13). In summary, Brazilian median 
incidence rates for all bone cancers followed the international 
pattern, where the highest rates were seen between the ages of 10 
and 19 years then decreasing gradually after 20 years of age. 
Considering only the current study, children showed a stable 
incidence rate, except for Sao Paulo that reported a decreased 
incidence rate. Historically, Sao Paulo, as the biggest Brazilian 
metropolitan city, receives patients from all over the country because 
has more specialized cancer centers. With the implementation of 
specialized centers capable of treating children with bone cancers 
across the country, less people move from their homes to receive 
treatment. Moreover, the Brazilian Osteosarcoma Treatment 
Group (BOTG) and the Brazilian Collaborative Study Group for 
the Treatment of Ewing Sarcoma Family Tumors (EWING1) have 
been collaborating to improve diagnosis and treatment (14,15). 
Considering the size of Brazilian population, for children and AYA, 
we would expect 360 and 180 new cases of OS and ES, respectively, 
per year. During 15 years of experience from BOTG, 778 cases 
(51 cases per year) were registered, corresponding to 14% of the 
estimated number of cases (25 participating institutions from 15 
cities). During the past eight years, 175 cases were included in 
the EWING1 register corresponding to 12% of estimated number 
of cases (15 institutions from Brazil and one institution from 
Uruguay). The efforts from the cooperative groups resulted in an 
increasing number of registered cases over the years, despite still 
being far below the expected number per year (15,16).
Among 25 countries distributed over five continents (Brazil 
not included), the median incidence rate of OS was 4.20 cases per 
million in males and 3.10 cases per million in females aged 0 to 24 
years (4). Among the AYA group, incidence rates of OS were also 
similar for different countries (11,17). However, we cannot make 
a full evaluation of the incidence rates by morphological subtypes 
over larger periods because these have not been described in 
Brazil since 1993, when an incidence rate of OS (3.9 per million) 
and ES (2.5 per million) among ages 0-14 years was described for 
Sao Paulo (18). 
In agreement with previous findings, OS and ES present different 
skeletal site distributions, with OS occurring more commonly 
in the long bones of lower limbs while ES were diagnosed more 
commonly in the long bones of upper limbs. Accordingly, these 
sites are adjacent to the growth plate, characterized by rapid growth 
during the adolescent spurt, reinforcing the relationship between the 
high cell cycle turnover due to bone growth and OS development 
(3,19). According to this hypothesis, we observed higher incidence 
rate for bone cancers among boys from 15-19 years old in the South 
and Midwest region in Brazil where the median height is higher 
(www.sidra.ibge.gov.br/tabela/2645).
Regarding the other bone cancers subtypes, we observed 
a higher incidence rate of NOS compared to the literature. 
Table 3 – Age-specific and age-adjusted mortality rates of bone tumors in children, adolescents and young adults from Brazil, SIM 
2009-2013.
Brazilian 0-4 5-9 10-14 15-19 20-24 25-29 0-14 15-29
Region ASMR ASMR ASMR ASMR ASMR ASMR AAMR AAMR
North 0.76 1.31 3.75 6.27 4.82 2.67 1.16 4.65
Northeast 0.50 1.63 3.93 7.00 4.51 2.87 1.21 4.88
Midwest 0.91 2.93 5.24 10.01 5.30 5.07 1.65 6.92
Southeast 0.86 1.63 3.44 6.64 4.40 2.86 1.09 4.72
South 0.56 1.60 4.78 8.45 5.66 2.78 1.46 5.74
BRAZIL 0.70 1.69 3.93 7.22 4.71 3.01 1.22 5.07
ASMR: Age-specific mortality rates; AAMR: Age-adjusted mortality rates.
Figure 2 – Joinpoint regression analysis of incidence and mortality trends by bone tumors in children, adolescents and young adults 
(0-29 years) in Brazil, according to PBCR and Brazilian regions.
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Diagnosis of bone cancers is usually performed using a 
combination of morphological and radiological features. However 
due to their rarity, only a centralized pathology and radiology 
reviews, secondary to the local review, would improve accuracy 
in diagnosis (20). Moreover, with the advance of basic and 
translational research, several biomarkers are being explored to 
meliorate the diagnosis (21).
Apart from a few established risk factors for OS and ES, little 
is known about the etiological pathways for bone cancers and 
their subtypes (3). Few cases of OS are attributed to germline 
mutations. Mutations in TP53 (Li-Fraumeni syndrome) and RB1 
(familial retinoblastoma syndrome) increase the risk to develop OS 
in 15- and 500-1000-fold compared with general population (17). 
Varying patterns of incidence of bone cancers are observed across 
countries, with a peak in teenage years observed particularly in high 
and mid-range incidence countries, suggesting some influence of 
the environment through epigenetic mechanisms (22). 
We observed a shift in the incidence with increasing and 
decreasing trend incidences of bone cancers in children and AYA 
groups, respectively. Although we have to be careful with this 
observation because most data did not show statistical significance, 
we might consider that age of puberty may be falling (23). 
An increasing trend of OS incidence was observed for females at 
younger ages, raising the question whether the earlier exposure to 
estrogen (due to the earlier puberty) could be involved with this 
shift. For instance, in older women from USA and UK, an increasing 
incidence rates of CS was reported for females but unchanged for 
males, coincident with the introduction of exogenous estrogen 
exposure by oral contraceptives and hormonal therapy when they 
were younger, giving some evidence that the relationship between 
estrogen exposure may have a role in bone cancer development 
(19).  
There is a lack of information about mortality trends in bone 
cancers in the literature, usually related to the availability of 
high-quality vital statistics (24). Mortality rates are affected by the 
quality of data on diagnosis and death certification, socioeconomic 
characteristics, and medical facilities specialized in pediatric 
oncology (25). The Mortality Information System was created in 
1975 in Brazil and in 2005, the Ministry of Health included a wide 
range of actions to improve the quality of death certifications, mainly 
in the North and Northeast regions. This improvement coincided 
with a decrease of ill-defined causes of mortality in 2010 (7,25). 
Agreeing with this technical bias, data from the BOTG comparing 
overall survival among children (aged less than 12 years) and AYA 
does not appear to be significantly different, suggesting that the 
participation in studies could improve prognosis (26).   
Mortality rates due to bone cancers increased with the 
advanced age. Among the children, AAMR was 1.22 cases per 
million compared to 5.07 cases per million in AYA, with no 
differences related to gender. A previous report performed in 
eight countries (including Brazil) showed an AAMR (2005-2007) 
of 1.20 cases per million in males and 3.58 cases per million in 
females in children aged 0 to 14 years, with Argentina showing 
the highest rates (2.10 and 2.40 cases per million in males and 
females, respectively) (24).   
Mortality rates due to bone cancers in the 15-29 years age 
group in USA were five cases per million in males and 2.50 cases 
per million in females. Mortality trends in the 0-14 year age group 
presented a slight increase (AAPC=0.3%) (15,16). In our analysis, 
the increase in AAPC was higher mainly in the North and Northeast 
regions in both age groups, as previously reported (7).  
In Great Britain, a greater risk of dying early for OS and ES 
was associated to living in more rural areas, which was linked to 
lower socio-economic factors or distance from specialist treatment 
centers (27). The most important prognostic factor for overall 
survival is the presence of metastases at diagnosis (19). BOTG and 
EWING1 demonstrated that the frequency of metastatic disease in 
Brazilians is high compared to other populations.
We discussed some limitations of this study throughout the 
text. It is worth to note the limitations of the 23 PBCR regarding 
the Brazilian population and territory size. Also, due to the rarity 
of bone cancers, especially subtypes other than OS, ES and CS a 
curate diagnosis remains challenging. Moreover, this rarity also 
prevented us to proper explore probable environmental factors 
potentially associated with bone cancer incidence rates across 
Brazilian regions. However, it is crucial to monitor cancer incidence 
and mortality trends across geographic regions, even if data are not 
complete, as this effort will enable to generate hypothesis related to 
genetic, epigenetic and environmental risk factors and point to at 
high risk groups that may need closer monitoring.  
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 ■ Appendix
Supplemental Table S1 - Data quality indicators of 23 Brazilian PBCR and your respective periods of information, according to 
International Agency for Research in Cancer (IARC).
PBCR
0-19 years   15-29 years
MV% DCO%   MV% DCO%
Aracaju (2007-2011) 100.0 0.0 100.0 0.0
Belém (2005-2009) 87.9 6.1 84.0 12.0
Belo Horizonte (2003-2007) 91.3 6.5 82.0 7.7
Campinas (2001-2005) 100.0 0.0 72.7 27.3
Cuiabá (2003-2007) 100.0 0.0 100.0 0.0
Curitiba (2006-2010) 97.14 2.86 96.6 3.4
Distrito Federal (1998-2002) 76.2 7.1 63.6 15.2
Florianópolis (2008-2012) 100.0 0.0 88.9 0.0
Fortaleza (2002-2006) 86.62 10.84 97.1 2.9
Goiânia (2005-2009) - - - -
Grande Vitória (2008-2012) 100.0 0.0 81.3 18.7
Jahu (2009-2013) 100.0 0.0 100.0 0.0
João Pessoa (2006-2010) 100.0 0.0 100.0 0.0
Manaus (2002-2006) 96.55 3.45 87.9 6.1
Natal (2001-2005) 78.57 7.14 83.3 0.0
Palmas (2008-2012) 100.0 0.0 75.0 25.0
Poços de Caldas (2007-2011) - - 50.0 0.0
Porto Alegre (2002-2006) 84.85 6.06 76.0 16.0
Recife (2006-2010) 95.0 5.0 81.3 6,3
Roraima (2006-2010) 100.0 0.0 40.0 20.0
Salvador (2001-2005) 84.62 5.13 76.9 2.6
São Paulo (2006-2010) - - - -
Teresina (2002-2006) 77.0  23.1    84.2 15.8 
- Data from Goiânia and São Paulo PBCR were not available
MV: Microscopic Verification; DCO: Death Certification Only
